Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer modelsSupreet Agarwal, Kathleen Kelly, Martine P. Roudier et al.|Journal of Clinical Investigation|2023Cited by 33
Stem cell dynamics and cellular heterogeneity across lineage subtypes of castrate-resistant prostate cancerMichael L. Beshiri, Kathleen Kelly, Brian J. Capaldo et al.|Stem Cells|2024Cited by 6
The origin and dynamics of cellular heterogeneity vary across lineage subtypes of castrate resistant prostate cancerMichael L. Beshiri, Kathleen Kelly, Brian J. Capaldo et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 3
Tumor-derived biomarkers beyond antigen expression enhance efficacy of CD276/B7H3 antibody-drug conjugate in metastatic prostate cancerSupreet Agarwal, Kathleen Kelly, Lei Fang et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 1